Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity. (August 2017)

Record Type:: Journal Article
Title:: Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity. (August 2017)
Main Title:: Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity
Authors:: Kulikowski, Ewelina
Calosing, Cyrus
Tsujikawa, Laura
Wasiak, Sylwia
Gilham, Dean
Halliday, Christopher
Johansson, Jan
Sweeney, Michael
Wong, Norman
Abstract:
Is Part Of:: Atherosclerosis. Volume 263(2017)
Journal:: Atherosclerosis
Issue:: Volume 263(2017)
Issue Display:: Volume 263, Issue 2017 (2017)
Year:: 2017
Volume:: 263
Issue:: 2017
Issue Sort Value:: 2017-0263-2017-0000
Page Start:: e113
Page End:
Publication Date:: 2017-08
Subjects:: Arteriosclerosis -- Periodicals
Electronic journals
616.136
Journal URLs:: http://www.sciencedirect.com/science/journal/00219150 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00219150 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/j.atherosclerosis.2017.06.363 ↗
Languages:: English
ISSNs:: 0021-9150
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1765.874000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 4426.xml